Debunking Myths About Ketamine-Assisted Therapy
Ketamine-assisted therapy is gaining recognition as a novel and effective treatment for a variety of mental health conditions. Despite its increasing use, there are still many misconceptions surrounding this treatment. In this article, we’ll address some of the common myths and provide clarity on what ketamine-assisted therapy truly offers.
Myth #1: Ketamine is Incompatible with Antidepressants
One of the most pervasive myths about ketamine-assisted therapy is that it cannot be used in conjunction with antidepressants. This is simply not true. Unlike other psychedelics, ketamine works through different neural pathways, specifically targeting the glutamate system rather than the serotonin system, which is the primary pathway affected by most antidepressants. As a result, ketamine does not interfere with antidepressant medications, making it safe for patients who are already taking them to undergo ketamine-assisted therapy.
Myth #2: Ketamine is Only for Treating Depression
While ketamine is most commonly associated with treating depression, it is far from being a one-trick pony. Research is expanding into its potential for treating a wide range of mental health conditions, including post-traumatic stress disorder (PTSD), anxiety disorders, and even chronic pain. Ketamine’s ability to enhance neuroplasticity— the brain’s ability to form new neural connections—opens up possibilities for its application in various therapeutic settings beyond depression.
Myth #3: Ketamine is Dangerous
Ketamine has garnered a reputation as a dangerous substance, largely due to its misuse in recreational settings such as nightclubs and parties. However, when administered by trained clinicians in a controlled environment, ketamine is remarkably safe. It has been used as an anesthetic in medical settings for decades, and its safety profile is well-established. In a therapeutic context, the dosage and purity of ketamine are carefully controlled, significantly reducing the risk of adverse effects.
Myth #4: Ketamine Causes Brain Damage
Concerns about ketamine causing brain damage often stem from instances of chronic abuse of the drug at high doses. However, in clinical use, ketamine does not cause brain damage. On the contrary, it may enhance neuroplasticity and promote the formation of new neural connections. This is one of the reasons why it is so effective in treating depression and other mental health conditions—it actually helps the brain heal and adapt in ways that traditional antidepressants may not.
Myth #5: Ketamine is Only Administered Intravenously
While intravenous (IV) ketamine infusions are the most well-known method of administration, they are not the only option available. Ketamine can also be administered via lozenges, which dissolve under the tongue, or through intramuscular or subcutaneous injections. These alternative methods provide flexibility and accessibility for patients, making ketamine-assisted therapy more convenient and personalized to individual needs.
Myth #6: Ketamine’s Effects are Fleeting
There is a misconception that the antidepressant effects of ketamine are only temporary. While it’s true that the immediate effects of ketamine may wear off after a few days or weeks, the integration of psychotherapy into ketamine-assisted treatment offers long-term benefits. When combined with therapy, ketamine can lead to sustained improvements in mental health, as the insights and changes brought about during treatment are reinforced and integrated into the patient’s life.
Myth #7: Ketamine Causes Prolonged Dissociation
Dissociative experiences are a known side effect of ketamine therapy, but they are usually brief and manageable with the help of a clinician. During treatment, patients may experience a feeling of detachment from their surroundings or body, but this effect is temporary and typically resolves soon after the session ends. Most patients return to normal functioning relatively quickly, and the dissociative effects are generally mild and short-lived.
Bonus Myth: Ketamine is Ineffective for Anxiety
Though ketamine is most commonly associated with treating depression, it is also showing promise in treating anxiety. While there is more research on ketamine’s effects on depression, studies have documented its efficacy in reducing anxiety symptoms and improving the quality of life for those suffering from anxiety disorders. As research continues to evolve, ketamine may become a valuable tool for addressing anxiety in addition to other mental health conditions.
Conclusion
Ketamine-assisted therapy is a powerful and emerging treatment that holds great promise for a variety of mental health conditions. By debunking these common myths, we hope to provide a clearer understanding of the potential benefits and limitations of ketamine therapy. When administered responsibly and as part of a comprehensive treatment plan, ketamine can offer a new path to healing for those struggling with mental health challenges.
References
Dore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., Monnette, C., Huidekoper, A., Strauss, N., & Wolfson, P. (2019). Ketamine-assisted psychotherapy (KAP): Patient demographics, clinical data, and outcomes in three large practices administering ketamine with psychotherapy. Journal of Psychoactive Drugs, 51(2), 189-198. https://doi.org/10.1080/02791072.2019.1587556
Feder, A., Costi, S., Rutter, S. B., Collins, A. B., Govindarajulu, U., Jha, M. K., Horn, S. R., Kautz, M., Corniquel, M., Collins, K. A., Bevilacqua, L., Glasgow, A. M., Friedman, S., Wang, Y., Hu, C., Iosifescu, D. V., Charney, D. S., & Murrough, J. W. (2021). A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. American Journal of Psychiatry, 178(3), 193-202. https://doi.org/10.1176/appi.ajp.2020.20050596
Grunebaum, M. F., Ellis, S. P., Keilp, J. G., Moitra, V. K., Cooper, T. B., Marver, J. E., Burke, A. K., Milak, M. S., Sublette, M. E., Oquendo, M. A., & Mann, J. J. (2018). Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam-controlled randomized clinical trial. Bipolar Disorders, 20(2), 113-122. https://doi.org/10.1111/bdi.12570
Kavalali, E. T., & Monteggia, L. M. (2020). Targeting homeostatic synaptic plasticity for treatment of mood disorders. Neuron, 106(5), 715-718. https://doi.org/10.1016/j.neuron.2020.05.025
Wilkinson, S. T., Toprak, M., Turner, M. S., Levine, S. P., Katz, R. B., & Sanacora, G. (2017). A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders. American Journal of Psychiatry, 174(7), 695-696. https://doi.org/10.1176/appi.ajp.2017.17020234